Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Breast Cancer, Triple Negative Breast Ca...
Phase PHASE3
Enrollment 764
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Antivascular therapy — BP102 (anti VEGFR)
  • Drug: Chemotherapy — ddEC-P

Primary Outcomes

  • iDFS (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-06-20
Completion: 2031-05-30
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 764 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhi-Ming Shao, MD, PhD
+86-021-64175590
zhimingshao@yahoo.com
HuiPing Li, MD
+86-010-88121122
Beijing Cancer Hospital
Xiaohua Zeng, MD
+86-023-65311341
Chongqing Cancer Hospital
Interventions
  • Drug: Antivascular therapy — BP102 (anti VEGFR)
  • Drug: Chemotherapy — ddEC-P
Study Locations (15 sites)
Beijing Cancer Hospital, Beijing, Beijing Municipality 100142 China
Chongqing Cancer Hospital, Chongqing, Chongqing Municipality 400030 China
Fujian Medical University Union Hospital, Fuzhou, Fujian 350001 China
Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital, Guangzhou, Guangdong China
Sun Yat-sen University Cancer Center, Guangdong, Guangzhou 510062 China
Affiliated Hospital of Nantong University, Nantong, Jiangsu 226006 China
Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225009 China
The First Hospital of China Medical University, Shenyang, Liaoning 110002 China
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning 110801 China
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: * Women aged 18-70 years old; * Eastern Oncology Collaborative Group (ECOG) physical status score: 0 or 1; * Histological results recorded as TNBC (negative HER2, ER, and PgR status) and BLIS subtype according to the classification of FUSCC; * Have stage IIA-IIIIC triple-negative breast cancer with non-metastatic surgically treated: pT1-3N1-3M0; * Adequate hematological and end-organ function as defined by the following laboratory test results, which need to be completed within 28 days prior to the first study treatment: absolute neutrophil count (ANC) ≥ 1500 cells/μL (no G-CSF support therapy within 2 weeks prior to day 1 of course 1); Platelet count ≥ 75×109/L (no platelet transfusion within 2 weeks before day 1 of course 1); hemoglobin ≥ 9.0 g/dL (no RBC transfusion within 2 weeks before day 1 of course 1); AST, ALT, and alkaline phosphatase ≤ 3 × upper limit of normal (ULN) serum total bilirubin ≤ 1.0 × ULN; serum creatinine ≤ 1ULN and with an endogenous creatinine clearance rate of \>50 ml/min (Cockcroft-Gault formula); * The surgical incision had fully healed prior to the commencement of the study; * Female participants of reproductive potential are required to use a medically accepted form of contraception during the course of the study treatment and for at least three months following the last administration of the investigational drug; * Sign the Informed Consent Form (ICF). The patient is judged by the investigator to have the ability to comply with the provisions of the protocol. Exclusion Criteria: * Has received neoadjuvant therapy (including chemotherapy, targeted therapy, and radiotherapy) * Has bilateral breast cancer; * Has a previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ. * Has metastatic (Stage 4) breast cancer; * Has any \>T4 lesion (UICC1987) (with skin involvement, mass adhesion and fixation, and inflammatory breast cancer); * Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (LVEF) \< 50% (a cardiac ultrasound); severe cardio cerebral vascular disease within the 6 months previous to randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\>150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension; * Is pregnant, breastfeeding women, or women of childbearing age who cannot practice effective contraceptives; * Patients participating in other clinical trials at the same time; * Has known allergy to taxane and excipients. * Has severe or uncontrolled infection; * Has a history of psychotropic substance abuse and was unable to abandon drug habits or those with a history of mental disorders; * the researchers judged patients to be unsuitable for the study.
Conditions Breast Cancer, Metastatic Breast Cancer,...
Phase Not Applicable
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This prospective observational study aims to evaluate serum levels of PTEN, a tumor suppressor gene, and organ-specific microRNAs (miRNAs) associated with metastatic patterns in breast cancer. Serum samples will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR)-based miRNA profiling and enzyme-linked immunosorbent assay (ELISA)-based PTEN quantification. Three groups will be included: patients with metastatic breast cancer (n=80), patients with non-metastatic early-stage breast cancer (n=40), and healthy controls (n=40). The primary objective is to identify serum biomarkers that differentiate metastatic from non-metastatic disease. Secondary analyses will evaluate correlations between biomarker levels and organ-specific metastatic involvement, including bone, lung, liver, and brain metastases. Findings from this study may support the development of a noninvasive serum-based tool for predicting metastatic patterns in breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Serum PTEN Level (At enrollment (single blood draw))
  • Serum microRNA (miRNA) Expression Levels (At enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-01
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Atlas University
Contact Information
Study Contact:
Emine Yildirim, MD
+905056234825
opdreyildirim@gmail.com
EMİNE YILDIRIM
+905056234825
opdreyildirim@gmail.com
Atlas University Faculty of Medicine
Hafize Uzun, PhD
90 535 542 11 47
hafize.uzun@atlas.edu.tr
Atlas University Faculty of Medicine
Interventions
N/A
Study Locations (1 sites)
Atlas University Faculty of Medicine, Istanbul, Istanbul 34403 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Female individuals aged ≥18 years * Ability to provide written informed consent * Group I (Metastatic BC): Histopathologically confirmed breast cancer and radiologically or clinically proven distant organ metastasis at the time of enrollment * Group II (Non-Metastatic BC): Histopathologically confirmed breast cancer with no evidence of distant metastasis * Group III (Healthy Controls): Women ≥18 years with no known breast disease and no personal history of malignancy Exclusion Criteria: * History of any other primary malignancy * Known breast disease or breast cancer diagnosis in Group III * Immunosuppressive therapy that may alter immune or biomarker profiles * Active infection or inflammatory condition that may alter biomarker levels * Inability or unwillingness to provide informed consent * Severe hepatic, renal, or hematologic dysfunction * Current pregnancy or lactation
Conditions Breast Cancer
Phase NA
Enrollment 3500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical study is to evaluate the potential benefits of intensified surveillance versus standard surveillance in medium-risk and high-risk early breast cancer patients. The main questions it aims to answer are: * Comparison of the 5-year ob´verall survival rates between patients in the Standard Surveillance arm versus patients in the liquid-biopsy guided Intensive Surveillance arm * Determination of the Overall Lead Time Effect generated due to tumor marker/CTC/ctDNA guided Intensive Surveillance compared to Standard Surveillance after primary therapy in early breast cancer patients. Participants will recieve regular blood drawals. Solely the blood samples of the intensive surveillance arm will be analysed for prospective tumor markers/CTCs/ctDNAs. Abnormal findings of either marker will trigger diagnostic imaging to search for possible metastases. The blood samples of the standard surveillance arm will solely be biobanked for future research purposes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: Quadruple

Interventions / Regimen

  • Diagnostic Test: Determination of tumormarkers (CA27.29, CEA, CA125) — CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal antibody that has been reconstituted in another cell (Cell-II) is dispensed into Cell-I. After second incubation, the magnetic microparticles are washed again and are incubated with a chemiluminescent substrate, DIFURAT®. The amount of enzyme-labeled antibodies that bind to the magnetic microparticles is directly proportional to the CA27.29/CEA/CA125 concentration in the test sample. A standard curve is constructed, unknown sample concentrations are calculated by using this curve.
  • Diagnostic Test: Determination of CTC levels — CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dispersion to a magnetic cartridge holder takes place. Via strong magnetic field, the magnetically labeled epithelial cells are attracted to the surface of the cartridge where they can be scanned automatically. Images of events where CK-PE and DAPI fluorescence are co-located are presented to the user for final classification. An event is classified as a tumor cell when its morphological features are consistent with that of a tumor cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45-.
  • Diagnostic Test: Determination of ctDNA levels — Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic variants. Patient specific primers are combined with common SNP primers for NGS for quality control purposes. To detect patient specific ctDNA, NGS testing is performed with the RaDaRTM assay using a multiplex PCR based on the InVision® platform.
  • Other: Biobanking of blood samples — To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.

Primary Outcomes

  • Overall Survival (OS) (10 years)
  • Overall Lead Time Effect (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-12-07
Completion: 2035-12
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 3500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Prof. Wolfgang Janni
Collaborators: German Federal Ministry of Education and Research
Principal Investigators:
  • Sophia Huesmann, Dr. (PRINCIPAL_INVESTIGATOR) - Universitätsklinikum Ulm
Contact Information
Study Contact:
Sophia Huesmann, Dr.
+4973150058577
sophia.huesmann@uniklinik-ulm.de
Forca Mehmeti, M.Sc.
+4973150058536
forca.mehmeti@uniklinik-ulm.de
survive.studie@uniklinik-ulm.de
University Hospital Ulm Gynecology/Obstetrics
Interventions
  • Diagnostic Test: Determination of tumormarkers (CA27.29, CEA, CA125) — CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal antibody that has been reconstituted in another cell (Cell-II) is dispensed into Cell-I. After second incubation, the magnetic microparticles are washed again and are incubated with a chemiluminescent substrate, DIFURAT®. The amount of enzyme-labeled antibodies that bind to the magnetic microparticles is directly proportional to the CA27.29/CEA/CA125 concentration in the test sample. A standard curve is constructed, unknown sample concentrations are calculated by using this curve.
  • Diagnostic Test: Determination of CTC levels — CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dispersion to a magnetic cartridge holder takes place. Via strong magnetic field, the magnetically labeled epithelial cells are attracted to the surface of the cartridge where they can be scanned automatically. Images of events where CK-PE and DAPI fluorescence are co-located are presented to the user for final classification. An event is classified as a tumor cell when its morphological features are consistent with that of a tumor cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45-.
  • Diagnostic Test: Determination of ctDNA levels — Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic variants. Patient specific primers are combined with common SNP primers for NGS for quality control purposes. To detect patient specific ctDNA, NGS testing is performed with the RaDaRTM assay using a multiplex PCR based on the InVision® platform.
  • Other: Biobanking of blood samples — To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.
Study Locations (1 sites)
University Hospital Ulm Gynecology/Obstetrics, Ulm, 89075 Germany
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures. 2. Unilateral or bilateral primary invasive carcinoma of the breast, confirmed histologically. 3. Patients with intermediate- to high-risk early breast cancer defined as either * an indication for (neo-)adjuvant chemotherapy (regardless whether performed or not), and/or * Large tumor (\> 50 mm), and/or * Positive lymph nodes, and/or * High grade (\>= G3). Indication to (neo-)adjuvant chemotherapy is seen as stated in the German S3 guideline for breast cancer as well as stated in the guidelines from the AGO. 4. A complete resection of the primary tumor, with resection margins free of invasive carcinoma. 5. Completion of primary anti-tumor therapy (adjuvant chemotherapy, surgery or radiotherapy, whichever occurs last) at least 4 weeks but no more than 24 months previously. Enrollment of patients during any kind of adjuvant therapy except chemotherapy (e.g., but not limited to endocrine therapy, antibody therapy, CDK4/6-inhibitors, PARP inhibitors, PI3K inhibitors, antibody-drug conjugates and other novel agents) is allowed. 6. Availability of primary tumor tissue from core biopsy or surgical removed tissue (FFPE Slide (≥ 6 mm³, min. 10 slides, thickness: 5 µm-10 µm, area \>150 mm² and 1 H\&E stained slide, minimum 20% tumor content) or FFPE Block (≥ 6 mm³ thickness: 100 µm, area: \>150 mm² and 1 H\&E stained slide, minimum 20% tumor content) or Genomic DNA extracted from FFPE slides or block (≥ 600 ng, Minimum volume: 25 µL, concentration: 20 ng/µL, buffer: 10 mM Tris pH 8, 1 mM EDTA)) at timepoint of enrollment. * Patients with primary systemic therapy: tissue from core biopsy * Patients receiving surgery as primary therapy: surgically removed cancer tissue. 7. No current clinical evidence for distant metastases. 8. Females or males ≥ 18 years and ≤ 75 years of age. 9. Performance status ≤ 1, Eastern Cooperative Oncology Group (ECOG) scale. 10. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. Exclusion Criteria: 1. Patients with a history of any secondary primary malignancy are ineligible with the following exceptions: * in situ carcinoma of the cervix or * adequately treated basal cell carcinoma of the skin or * ipsi- or contralateral non-invasive carcinoma of the breast (DCIS). 2. Patients in pregnancy or breastfeeding. If a patient gets pregnant during the participation in the interventional phase of the study (Year 1-5), an end of intervention visit will be scheduled and the patient will enter the follow-up phase of the study. Pregnancy during the follow-up phase of the study is to be reported but does not lead to an exclusion of the study. 3. History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent. 4. Renal insufficiency with GFR \< 30 mL/min. 5. Previous or concomitant cytotoxic or other systemic antineoplastic treatment that is not used for treating the primary breast cancer.
Conditions Type 2 Diabetes
Phase PHASE4
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The current study aimed to thoroughly compare a thiazolidinedione and an sodium-glucose cotransporter-2 (SGLT2) inhibitor regarding various clinical issues including atherosclerosis. Enavogliflozin is compared to Pioglitazone in the glucose-lowering effects of adding to the treatment of patients with type 2 diabetes whose HbA1c levels are not controlled by Metformin with or without DPP-4 inhibitors. Additionally, the study will compare changes in other metabolic or cardiovascular risk factors, such as triglycerides, high density lipoprotein cholesterol (HDLc), uric acid, blood pressure, and inflammatory markers, between the two drugs.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Enavogliflozin — Enavogliflozin 0.3mg once daily
  • Drug: Pioglitazone — Pioglitazone 15mg once daily

Primary Outcomes

  • Changes of HbA1c from the baseline (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-02-01
Completion: 2027-12-31
Eligibility
Age: 20 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Bundang Hospital
Collaborators: Daewoong Pharmaceutical Co. LTD.
Principal Investigators:
  • Soo Lim, M.D. Ph.D. (PRINCIPAL_INVESTIGATOR) - Seoul National University Bundang Hospital
Contact Information
Study Contact:
Soo Lim, M.D. Ph.D.
+82317877035
limsoo@snu.ac.kr
Minji Sohn, Ph.D.
+82317878443
rainbowmjs@naver.com
Soo Lim
+82317877035
limsoo@snu.ac.kr
Seoul National University Bundang Hospital
Interventions
  • Drug: Enavogliflozin — Enavogliflozin 0.3mg once daily
  • Drug: Pioglitazone — Pioglitazone 15mg once daily
Study Locations (1 sites)
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do 13620 South Korea
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes patients with a glycated hemoglobin (HbA1c) level of 7.0 - 10.5% at screening * Males or females aged 20-80 years * Individuals who have been taking Metformin (≥ 500mg) with or without a DPP-4 inhibitor (such as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Alogliptin, Teneligliptin, Anagliptin, Evogliptin) for at least the past 3 months * Body mass index ≥ 23 kg/m² * Estimated glomerular filtration ratio (eGFR) ≥ 60 ml/min/1.73m² Exclusion Criteria: * Patients with Type 1 Diabetes, Gestational Diabetes, or secondary diabetes due to other causes * Patients with a history of acute cardiovascular disease within the last 3 months prior to the screening visit * Pregnant or breastfeeding patients, or patients not using contraception. Patients with chronic Hepatitis B or C (excluding healthy carriers of Hepatitis B), or liver disease (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 3 times the upper limit of normal) * Patients with heart failure or a history of heart failure * Individuals with a history of cancer within the past 5 years (excluding those adequately treated for squamous cell carcinoma or thyroid cancer) * Patients who have participated in another clinical study within the last 30 days * Alcohol addiction * Patients for whom the use of Enavogliflozin or Pioglitazone is contraindicated * Patients taking other oral hypoglycemic agents or insulin or other investigational drugs * Patients deemed unsuitable for the study based on the investigator's judgment
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Metformin is a drug frequently prescribed to patients with type 2 diabetes. Furthermore, diabetes can lead to micro- and macrovascular complications that may cause chronic organ failure. The presence of diabetes also increases the risk of infections. All of these factors contribute to the frequent admission of patients to the ICU who have been receiving metformin treatment in the preceding days. Acute renal failure, which is also frequently observed upon admission to the ICU, increases the risk of metformin overdose. In cases of overdose, metformin acts on several metabolic pathways that can lead to or even accelerate metabolic acidosis, sometimes severe. However, the impact on prognosis is controversial. The role of metformin in lactic acidosis in patients treated for acute illness may be underestimated in routine practice. This study aims to investigate the impact of prior metformin treatment on ICU survival in patients admitted to the ICU with severe lactic acidosis.

Design

Study type: Observational Observational model: Case Control Time perspective: Retrospective

Primary Outcomes

  • Survival rates of patients with severe lactic acidosis admitted to the ICU after prior metformin treatment (Up to 18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-06
Completion: 2026-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Strasbourg, France
Contact Information
Study Contact:
Vincent CASTELAIN, MD, PhD
33 3.88.12.79.15
vincent.castelain@chru-strasbourg.fr
Vincent CASTELAIN, MD, PhD
33 3.88.12.79.15
vincent.castelain@chru-strasbourg.fr
Service de Médecine Intensive - Réanimation - CHU de Strasbourg - France
Vincent CASTELAIN, MD, PhD
Service de Médecine Intensive - Réanimation - CHU de Strasbourg - France
Interventions
N/A
Study Locations (1 sites)
Service de Médecine Intensive - Réanimation - CHU de Strasbourg - France, Strasbourg, 67091 France
Eligibility Criteria
Inclusion Criteria: * Adult patient (≥18 years) * Admitted to the intensive care unit of Hautepierre Hospital - Strasbourg University Hospital between January 1, 2014, and December 31, 2023 * Having experienced lactic acidosis (pH \<7.35 and lactate level ≥5 mmol/L) within the first 24 hours of hospitalization. Exclusion Criteria: * Patient without arterial blood gas measurements during the first 24 hours of admission * whose background treatment is unknown and could not be determined * for whom a limitation of active therapies was implemented before or during the first 24 hours of hospitalization
Conditions Diabetes
Phase PHASE1
Enrollment 134
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) biomarkers in single ascending doses (SAD), food effect, and multiple doses studies of RZ-629 in healthy participants and T2D.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: RZ-629 — Administered orally
  • Drug: Placebo — Administered orally
  • Other: Fasted — Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout
  • Other: Fed — Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout

Primary Outcomes

  • Number of participants reporting 1 or more treatment-emergent adverse events (Baseline to day 7)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-01-30
Completion: 2026-02-20
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 134 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rezubio Pharmaceuticals Co., Ltd.
Contact Information
Study Contact:
Dr. Tang
086-7566881098
yongsong.tang@rezubio.com
Thomas Polasek, MD, PhD
0458 162 715
thomas.polasek@cmax.com.au
CMAX
Thomas Polasek, MD, PhD
CMAX
Interventions
  • Drug: RZ-629 — Administered orally
  • Drug: Placebo — Administered orally
  • Other: Fasted — Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout
  • Other: Fed — Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout
Study Locations (1 sites)
CMAX, Adelaide, Australia
Eligibility Criteria
Inclusion Criteria: 1. Sign the informed consent form (ICF) before the study, and fully understand the content, process and possible adverse reactions of the trial. 2\. Healthy male or female subjects between the ages of 18 and 65 years, inclusive. 3\. For part 1, part 2 and part 3 in healthy participants, minimum body weight is 50 kg for males, and 45 kg for females, have a BMI of 18 to 32 kg/m2, inclusive. For part 3 in T2D, BMI is between 25 to 40 kg/m2, inclusive. 4\. For part 1, part 2, and part 3 in healthy participants, fasting plasma glucose is between 3.9 mmol/L (70.2 mg/dL) and 6.1 mmol/L (109.8 mg/dL) at screening. For part 3 in T2D, glycosylated hemoglobin A1c (HbA1c) is between 6.5% and 10.5%, inclusive, and FPG ≤ 13.3 mmol/L at screening. 5\. For part 1, part 2, and part 3 in healthy participants, participants are in good health, with no clinically relevant acute or chronic medical conditions or severe diseases of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, respiratory, blood, immune or dermatological systems, as judged by the investigator. For part 3 in T2D, participants are diagnosed with T2DM for more than 1 year, and on a stable dose of dipeptidyl peptidase IV inhibitor (DPP-4i) monotherapy or DPP-4i + Metformin as their only anti-hyperglycemic treatment for at least 3 months prior to the screening visit. 6\. With no clinically significant findings from vital signs measurements, physical examination, clinical laboratory evaluations and 12-lead ECG, as judged by the investigator. 7\. Subjects must be willing to understand and comply with all research procedures and restrictions and be able to communicate effectively with researchers. Exclusion Criteria: 1. With a specific history of allergies or known to have multiple allergies. 2\. Have experienced acute illnesses within 2 weeks prior to the first dose or are taking concomitant medications. 3\. With a history or current presence of dysphagia or diseases that may potentially interfere with drug absorption or metabolism. 4\. Subjects and their first-degree relatives with a history of diabetes before screening. 5\. With a history of hypoglycemia or with impaired awareness or cognition of hypoglycemic symptoms within 3 months prior to screening. 6\. History of previous corrected QT interval (QTc) prolongation or clinically abnormal electrocardiogram (ECG) finding during screening. 7\. Have undergone major surgery within the past 6 months, or those planning to undergo surgery during the study period. 8\. Have used any medications and dietary supplements within 2 weeks prior to the first dose. 9\. Within 48 h prior to the first dose, have consumed food or beverages containing caffeine, alcohol, or concentrated tea, or those who have consumed special diets and/or purine-rich diets or have other factors that may affect drug absorption, distribution, metabolism, or excretion. 10\. Have received vaccinations within 4 weeks prior to the first dose or plan to receive vaccinations during the trial. 11\. Have participated in other clinical trials within 3 months prior to the first dose, or those planning to participate in other trials during the study period. 12\. Have donated blood and blood products (including plasma) within 3 months prior to the first dose or have experienced non-physiological blood loss of ≥ 400 mL within 6 months. 13\. Have consumed an average of more than 14 units of alcohol per week within the past 12 months prior to screening. 14\. Have smoked more than 5 cigarettes per day within the past 3 months or cannot stop using any tobacco products during the study. 15\. With a history of drug abuse within the past 12 months or positive drug abuse at screening. 16\. With positive results for serology of infectious diseases at screening. 17. Cannot tolerate venipuncture/indwelling needle or have a history of vasovagal syncope. 18\. Subjects deemed unsuitable for participation in this trial by the investigator due to other factors. 19\. With chronic or acute gastrointestinal inflammation. 20. Abnormal liver function tests: ALT or AST \> 2×ULN, or TBIL \> 1.5×ULN. 21. Use of drugs that may affect glucose metabolism (e.g., systemic steroids, nonselective β-blockers, monoamine oxidase inhibitors) within 1 month prior to screening.
Conditions Hypercortisolism, Type 2 Diabetes (T2DM)
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to explore the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes despite receiving standard-of-care therapies. Additionally, the study will evaluate the correlation between salivary cortisol levels and glycemic control.

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Primary Outcomes

  • Prevalence of Hypercortisolism (Baseline (Screening))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-11
Completion: 2027-12-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai 6th People's Hospital
Contact Information
Study Contact:
Jian Zhou
+86-021-64369181
zhoujian@sjtu.edu.cn
Jiaying Ni, B.S.
021-24056515
njy1997@sjtu.edu.cn
Shanghai Sixth People's Hospital
Interventions
N/A
Study Locations (1 sites)
Shanghai Sixth People's Hospital, Shanghai, 200233 China
Eligibility Criteria
Inclusion Criteria: 1. Aged between 18 and 80 years. 2. Meets the definition of difficult to control type 2 diabetes: HbA1c level between 7.5% and 11.5%, AND Taking 3 or more anti-hyperglycemic drugs. OR Taking insulin and other anti-hyperglycemic drugs. OR Taking 2 or more anti-hyperglycemic drugs AND a.) the presence of 1 or more micro-vascular or macro-vascular complication (retinopathy, diabetic nephropathy and chronic kidney disease, diabetic neuropathy, atherosclerotic heart disease with diabetes); AND/OR b.) concomitant hypertension requiring 2 or more anti-hypertension medications. Exclusion Criteria: 1. Patients with Type 1 diabetes, new-onset diabetes (\<1 year duration), or other specific types of diabetes. 2. History of systemic glucocorticoid use within the last 3 months (inhaled or topical agents are not exclusionary). 3. Pregnant or lactating. 4. Presence of severe cardiac, hepatic, renal, or other major organ dysfunction. 5. History of acute diabetic complications, such as diabetic ketoacidosis or hyperosmolar hyperglycemic state, within the last 3 months. 6. Presence of diseases that significantly affect metabolism, such as malignancy or autoimmune disorders. 7. Inability to tolerate adhesive tape, severe skin conditions at the sensor placement site, or presence of a psychiatric illness or cognitive impairment that would interfere with study compliance. 8. A known diagnosis of Cushing's syndrome, or currently receiving treatment with any of the following: mifepristone, metyrapone, osilodrostat, ketoconazole, fluconazole, aminoglutethimide, etomidate, octreotide, larazotide, long-acting octreotide, or pasireotide. 9. Excessive alcohol consumption (defined as \>14 units per week for males or \>7 units per week for females). 10. Severe, untreated sleep apnea. 11. Night shift workers (defined as being awake between 11:00 PM and 7:00 AM). 12. Known allergy or severe reaction to dexamethasone.
Conditions Obesity & Overweight, Type 2 Diabetes, T...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Hydration Plus — The hydration plus intervention aims to increase hydration through employing the following behavior change strategies/techniques: coaching (consisting of goal setting, making a plan, and coping planning), positive feedback, and utilize a contingency management payment schedule wherein participant earned amount hinges on them meeting their goal.
  • Behavioral: Control — Participants randomly assigned to the control group will receive information on hydration and will receive prompts to drink.

Primary Outcomes

  • Acceptability of hydration plus (At week 16, which is the end of the program.)
  • Feasibility of Intervention (At week 16, which is the end of the program.)
  • Change in physiological hydration score (Baseline (week 0) to week 16 (post - program))
  • Change in perceived hydration level (Week -1 (run - in week) to week 16 (end of program))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-24
Completion: 2027-02-01
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: State University of New York at Buffalo
Collaborators: National Institutes of Health (NIH)
Principal Investigators:
  • Katherine N Balantekin, PhD, RD (PRINCIPAL_INVESTIGATOR) - University at Buffalo
  • Elizabeth G Mietlicki-Baase, PhD (PRINCIPAL_INVESTIGATOR) - University at Buffalo
  • Leonard H Epstein, PhD (PRINCIPAL_INVESTIGATOR) - University at Buffalo
Contact Information
Study Contact:
Hannah E Kolpack, BS
(716) 829 - 5820
hkolpack@buffalo.edu
State University of New York at Buffalo, South Campus
Katherine N Balantekin, PhD, RD
State University of New York at Buffalo, South Campus
Elizabeth G Mietlicki-Baase, PhD
State University of New York at Buffalo, South Campus
Interventions
  • Behavioral: Hydration Plus — The hydration plus intervention aims to increase hydration through employing the following behavior change strategies/techniques: coaching (consisting of goal setting, making a plan, and coping planning), positive feedback, and utilize a contingency management payment schedule wherein participant earned amount hinges on them meeting their goal.
  • Behavioral: Control — Participants randomly assigned to the control group will receive information on hydration and will receive prompts to drink.
Study Locations (1 sites)
State University of New York at Buffalo, South Campus, Buffalo, New York 14214 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged 18-60 * Recently prescribed a GLP-1RA (within one week of prescription) * Fluent in English * Willing to complete the study protocol Exclusion Criteria: * Children and adults \> 60 years of age * Those not taking a GLP-1RA * Those who have been on a GLP-1RA longer than one week * Not fluent in English * Those who are pregnant or planning on becoming pregnant during the duration of the study * Unwilling to comply with study protocol * People with cardiac implants
Conditions Cardiovascular Autonomic Neuropathy, Typ...
Phase PHASE2
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Diabetic neuropathy is a serious and common complication of diabetes that currently has no cure. One form of this condition is cardiovascular autonomic neuropathy (CAN), which affects about 20% of people with diabetes-an estimated 100 million people worldwide. CAN is a significant risk factor for death and health problems like heart disease and kidney damage, and may contribute to the high rates of cardiovascular-related deaths in people with diabetes. This study is a double-blind, randomized, placebo-controlled, two-center trial. The study aims to test whether finerenone can treat cardiovascular autonomic neuropathy in patients with type 2 diabetes. The trial will evaluate the effects of 78 weeks of treatment with finerenone or a placebo, assigned randomly in a 1:1 ratio, on early-stage cardiovascular autonomic neuropathy. The trial will include 100 participants with type 2 diabetes. Additionally, the study will investigate how the treatment impacts other types of neuropathy and related pathological mechanisms.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Kerendia (Finerenone, BAY94-8862) — Titration of finerenone will be based on baseline eGFR. Participants with eGFR \> 60 mL/min/1.73m² will start on a 20mg dosage. Medication dosage will be increased to 40 mg after one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level. Participants with eGFR \< 60 and \>25 Participants with eGFR \< 60 mL/min/1.73m² (and eGFR \< 25 mL/min/1.73m²) will start on a 10mg dosage. Medication dosage will be increased to 20 mg after one month if serum potassium \< 4.8 mmol/l. Subsequently, Medication dosage will be increased to 40 mg after an additional one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level. Finerenone is administered orally as immediate release tablets.
  • Drug: Placebo — Placebo tablets matching BAY94-8862 are administered orally.

Primary Outcomes

  • Between-group (finerenone vs. placebo) difference in changes on the CART E/I ratio (From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-02
Completion: 2028-01
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peter Rossing
Collaborators: Steno Diabetes Center Nordjylland, Aarhus University Hospital
Principal Investigators:
  • Peter Rossing, Professor, MD (PRINCIPAL_INVESTIGATOR) - Steno Diabetes Center Copenhagen
Contact Information
Study Contact:
Peter Rossing, Professor, MD
+4530913383
peter.rossing@regionh.dk
Christian Stevns Hansen, Ph.D, MD
+4561671618
christian.stevns.hansen@regionh.dk
Asbjørn Mohr Drewes, MD, professor
99321111
amd@rn.dk
Steno Diabetes Center Northern Denmark
Interventions
  • Drug: Kerendia (Finerenone, BAY94-8862) — Titration of finerenone will be based on baseline eGFR. Participants with eGFR \> 60 mL/min/1.73m² will start on a 20mg dosage. Medication dosage will be increased to 40 mg after one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level. Participants with eGFR \< 60 and \>25 Participants with eGFR \< 60 mL/min/1.73m² (and eGFR \< 25 mL/min/1.73m²) will start on a 10mg dosage. Medication dosage will be increased to 20 mg after one month if serum potassium \< 4.8 mmol/l. Subsequently, Medication dosage will be increased to 40 mg after an additional one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level. Finerenone is administered orally as immediate release tablets.
  • Drug: Placebo — Placebo tablets matching BAY94-8862 are administered orally.
Study Locations (2 sites)
Steno Diabetes Center Northern Denmark, Gistrup, 9260 Denmark
Steno Diabetes Center Copenhagen, Herlev, 2730 Denmark
Eligibility Criteria
To be included in this study the participants must fulfill the following inclusion criteria. * Given informed consent * Type 2 diabetes defined by WHO criteria * Aged 40 ≥ at inclusion * Pathological E/I ratio (Mean value of three measures) Exclusion criteria Participants will be excluded in one or more of the following criteria are met. * No CAN (no abnormal CARTs) * Definite CAN (more than one abnormal CART) * HbA1C \>100 mmol/L * Treatment with potassium-sparing diuretics (amiloride) or MRAs e.g., spironolactone or eplerenone which cannot be discontinued 4 weeks prior to screening visit. The patient's primary physician, who is not involved in this study, will determine if discontinuation is possible. * Atrial fibrillation/flutter * Congestive heart failure (NYHA class 3-4) * History of cardiac arrhythmia * Severe forms of respiratory disease including asthma and COPD * Any nondiabetic cause of neuropathy * All female subjects of childbearing potential (WOCBP) must have a negative result of a highly sensitive urine HCG (pregnancy test) performed at screening. Subjects of childbearing potential must agree to use a highly effective form of contraception throughout the duration of the study (list of definition on WOCBP and accepted contraception in appendix A). * Severe hepatic impairment * Lactose intolerance * Breastfeeding * Nephropathy requiring dialysis * Beta-blocker-use * Hyperkalemia at screening visit (plasma potassium \>4.8 mmol/l) * eGFR \< 25 ml/min/1.73m2 * Potassium plasma \> 4.8 mmol/l (at randomization) * Treatment with strong CYP3A4-inhibitors (e.g. Itraconazol, ketoconazol, ritonavir, cobicistat, clarithromycin) which cannot be discontinued 4 weeks prior to screening visit * Treament with moderate to strong CYP3A4-induceres (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital, St John's Wort or efavirenz) which cannot be discontinued 4 weeks prior to screening visit * Have received chemotherapeutic treatment within last 12 months * Grapefruit consumption that cannot be discontinued during the study period * Inability to complete study protocol, assessed to investigator * Not able to read, write and/or understand Danish
Conditions Genetic Predisposition, Metabolic Diseas...
Phase PHASE4
Enrollment 125
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance test (MMTT) before and after a 14-day treatment with oral semaglutide. The investigators will do this by measuring factors in the blood, such as sugars, fats, metabolites, and proteins, after eating a standardized breakfast meal at the first visit and after taking 14 doses of oral semaglutide over two weeks before the second study visit. The food (mixed meal breakfast) we will be studying is specially prepared to contain a set amount of protein, carbohydrates, and fat. The investigators hypothesize that understanding how the acute biochemical response to oral semaglutide differs by genetic variation will generate insight into drug mechanisms and type 2 diabetes pathophysiology.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: oral semaglutide — Semaglutide is the only oral glucagon-like peptide 1 receptor agonist (GLP-1 RA) approved for treatment of type 2 diabetes. Participants will receive 7 mg of oral semaglutide once daily for 14 days in between Visit 1 and Visit 2.
  • Other: Mixed Meal Tolerance Test (MMTT) — The MMTT is developed by the Metabolism and Nutrition Metabolic Kitchen at the MGH TCRC. The meal is a high-calorie, high-carbohydrate and moderate-to-high glycemic index challenge composed of commonly consumed breakfast food items. It provides nearly 90 grams of carbohydrates and mimics an oral glucose challenge. The participants will undergo a MMTT at Visit 1 and Visit 2.

Primary Outcomes

  • Insulin response to oral semaglutide treatment (15 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-03-12
Completion: 2027-05-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 125 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Josephine Li, MD (PRINCIPAL_INVESTIGATOR) - MGH
Contact Information
Study Contact:
Varinderpal Kaur
6176435419
vkaur@mgh.harvard.edu
Josephine Li
617-643-4987
jli71@mgh.harvard.edu
Varinderpal Kaur
6176435419
vkaur@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Drug: oral semaglutide — Semaglutide is the only oral glucagon-like peptide 1 receptor agonist (GLP-1 RA) approved for treatment of type 2 diabetes. Participants will receive 7 mg of oral semaglutide once daily for 14 days in between Visit 1 and Visit 2.
  • Other: Mixed Meal Tolerance Test (MMTT) — The MMTT is developed by the Metabolism and Nutrition Metabolic Kitchen at the MGH TCRC. The meal is a high-calorie, high-carbohydrate and moderate-to-high glycemic index challenge composed of commonly consumed breakfast food items. It provides nearly 90 grams of carbohydrates and mimics an oral glucose challenge. The participants will undergo a MMTT at Visit 1 and Visit 2.
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: 1. Males or non-pregnant females 2. Ages 18-65 (inclusive) 3. Able/willing to give consent 4. Span the metabolic range between normal glycemia and pre-diabetes (fasting glucose of 100-125 mg/dL based on chart review of existing laboratory data) Exclusion Criteria: 1. Currently taking medications or intending to take medications for diabetes 2. Currently taking medications or intending to take medications that affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones 3. Personal history of intestinal malabsorption, bariatric surgery, celiac disease, gallbladder disease, or pancreatitis 4. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 5. Estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m2 per the Modification of Diet in Renal Disease equation 6. History of cirrhosis and/or aspartate aminotransferase or alanine aminotransferase more than 3x upper limit of normal 7. Dietary restrictions preventing consumption of a MMTT 8. Women who are pregnant, nursing, or at risk of becoming pregnant 9. Participation in other interventional studies during the current study
Conditions Type 2 Diabetes, Appetite Regulation, Wh...
Phase NA
Enrollment 32
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this placebo-controlled, partial crossover design study is to identify the impact of consuming whey protein before meals on free-living glucose control in older adults living with type 2 diabetes. The primary specific objective is to determine the effect of a thrice daily whey protein pre-meal supplementation at two doses, on glucose excursions over a 7-day free-living period in adults aged 70-90 years of age, living with type 2 diabetes, compared with a non-protein placebo. Participants will consume the whey protein and placebo for 7 days each, before each meal. All participants will consume the placebo and one of two doses of whey protein, in a randomised order.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Glycaemic control with whey protein — Comparing pre-meal supplementation of whey protein to protein-free placebo.
  • Dietary Supplement: Glycaemic control with different doses of whey protein — Comparing pre-meal supplementation of moderate whey protein to a low dose of whey protein.

Primary Outcomes

  • Measurement of changes in free-living glycaemic control (7 days, two occasions)
  • Changes in postprandial glucose concentrations in blood (4 hours, two occasions)
  • Concentrations of insulin postprandially in blood (4 hours, two occasions)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-02
Completion: 2027-05-31
Eligibility
Age: 70 Years – 90 Years
Sex: ALL
Volunteers: true
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Birmingham
Collaborators: Newcastle University
Principal Investigators:
  • Leigh Breen, PhD (PRINCIPAL_INVESTIGATOR) - University of Birmingham and University of Leciester
Contact Information
Study Contact:
Leigh Breen, PhD
(0)1214144109
l.breen@bham.ac.uk
Marie Korzepa, PhD
m.korzepa@bham.ac.uk
Srikanth Bellary, MD
4240234
Heartlands Hospital
Interventions
  • Dietary Supplement: Glycaemic control with whey protein — Comparing pre-meal supplementation of whey protein to protein-free placebo.
  • Dietary Supplement: Glycaemic control with different doses of whey protein — Comparing pre-meal supplementation of moderate whey protein to a low dose of whey protein.
Study Locations (2 sites)
School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, West Midlands B15 2TT United Kingdom
Heartlands Hospital, Birmingham, United Kingdom
Eligibility Criteria
* Male or female * 70-90 years old * Type 2 Diabetes (confirmed with glycated haemoglobin (HbA1c) \>6.5% in clinic or in SportExR) * Stable body mass (body mass index (BMI) ≤40kg/m2) * Generally healthy, assessed via a General Health Questionnaire (GHQ) * Some residual beta-cell activity (confirmed with urine test on induction) * Normal or moderately increased albuminuria (needs to be below 300mg/g) * Normal, mildly or moderately decreased glomerular filtration rate (GFR) (needs to be above 45ml/min/1.732). * Able and willing to attend SportExR a total of 5 times: 1 induction and 2 testing visits and 2 return check-up visits. Exclusion Criteria: * \<70 years old and over 90 years of age * Currently on fast-acting insulin therapy (i.e., Humalog) * Confirmed uncontrolled diabetes (HbA1C \>10% or 85mmol/mol). * Currently on GLP-1 therapy * Habitual smoker or vaper * Veganism * Lactose or dairy intolerance * Coeliac or gluten intolerance * History of gastrointestinal disease * Experienced a hyperglycaemic or hypoglycaemic event requiring treatment in the past 12 months * Recent Ischemic stroke (\<3 months). * Use of anticoagulants (e.g. warfarin, rivaroxaban) * Considered unwilling or unable to comply with the study protocol requirements by the research team
Conditions Type 2 Diabetes Mellitus (T2DM)
Phase Not Applicable
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Type 2 Diabetes Mellitus (T2DM) is a multifaceted metabolic disease associated not only with impaired glycemic control but also with reductions in muscle strength, balance, functional mobility, and walking performance. Individuals with T2DM may experience impairments in lower extremity function, postural control, and overall functional performance, which can negatively affect activities of daily living and quality of life. Therefore, the assessment of functional performance using reliable and valid methods is important for clinical monitoring and rehabilitation planning. The 6-Minute Walk Test (6MWT), Timed Up and Go Test (TUG), and Five-Repetition Sit-to-Stand Test (5xSTS) are widely used clinical assessments for evaluating walking capacity, functional mobility, lower extremity function, and physical performance in individuals with T2DM. Previous studies have demonstrated that these tests provide reliable and clinically meaningful measurements in this population. In recent years, virtual and mixed reality technologies have provided opportunities to conduct assessments in a more objective, standardized, and user-friendly manner. These technologies also offer important advantages, including real-time data collection, enhanced user interaction, and potential integration into future remote assessment applications. However, evidence regarding the measurement properties of mixed reality-based adaptations of commonly used functional performance tests in individuals with T2DM remains limited. The aim of this study is to evaluate the validity and reliability of mixed reality-based adaptations of the 6-Minute Walk Test, Timed Up and Go Test, and Five-Repetition Sit-to-Stand Test developed using the Meta Quest 3 platform. In addition, convergent validity will be examined by investigating the relationships between outcomes obtained from the mixed reality-based assessments and measures of knee extensor muscle strength and handgrip strength. The findings of this study are expected to contribute to the development of innovative, safe, standardized, and digital approaches for assessing functional performance in individuals with Type 2 Diabetes Mellitus. Furthermore, the results may provide a scientific foundation for future digital health applications and remote assessment strategies.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Mixed Reality-Based Functional Performance Assessment — Participants will perform mixed reality-based adaptations of the 6-Minute Walk Test (6MW-MR), Timed Up and Go Test (TUG-MR), and Five-Repetition Sit-to-Stand Test (5xSTS-MR) developed for the Meta Quest 3 platform. The mixed reality environment digitally replicates the conventional test setups and provides standardized visual guidance while allowing participants to interact safely with the real environment. Test outcomes will be automatically recorded by the system and compared with conventional clinical assessments to evaluate validity. The mixed reality-based tests will be repeated one week later to assess test-retest reliability.

Primary Outcomes

  • 6-Minute Walk Test - Mixed Reality (6MW-MR) (Baseline and 1-week follow-up)
  • Timed Up and Go Test - Mixed Reality (TUG-MR) (Baseline and 1-week follow-up)
  • Five-Repetition Sit-to-Stand Test - Mixed Reality (5xSTS-MR) (Baseline and 1-week follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-10
Completion: 2027-05-10
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Selcuk University
Principal Investigators:
  • İsmail ÖZSOY, Assoc. Prof. Dr. (STUDY_CHAIR) - Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Konya, Türkiye
  • Zehra KORKUT, Assist. Prof. Dr. (STUDY_CHAIR) - Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Konya, Türkiye
  • Gülşah ÖZSOY, Assist. Prof. Dr. (STUDY_CHAIR) - Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Konya, Türkiye
Contact Information
Study Contact:
Mehmet K ALTUNOK, PHD(c) in PT
5558175133
mehmetkaan.altunok@selcuk.edu.tr
Mehmet K ALTUNOK, PHD(c) in PT
5558175133
mehmetkaan.altunok@selcuk.edu.tr
Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation
Interventions
  • Other: Mixed Reality-Based Functional Performance Assessment — Participants will perform mixed reality-based adaptations of the 6-Minute Walk Test (6MW-MR), Timed Up and Go Test (TUG-MR), and Five-Repetition Sit-to-Stand Test (5xSTS-MR) developed for the Meta Quest 3 platform. The mixed reality environment digitally replicates the conventional test setups and provides standardized visual guidance while allowing participants to interact safely with the real environment. Test outcomes will be automatically recorded by the system and compared with conventional clinical assessments to evaluate validity. The mixed reality-based tests will be repeated one week later to assess test-retest reliability.
Study Locations (1 sites)
Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Konya, Selcuklu 42130 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Diagnosed with Type 2 Diabetes Mellitus by a physician, * Aged between 18 and 65 years, * Ability to ambulate independently without the use of an assistive device, * No participation in a structured exercise program within the previous 6 months, * Cognitive ability sufficient to understand and follow test instructions, * Visual, auditory, and vestibular functions sufficient to tolerate mixed reality applications, * Ability to read, understand, and follow instructions in Turkish, * Willingness to participate voluntarily in the study and provision of written informed consent. Exclusion Criteria: * Presence of proliferative diabetic retinopathy or severe non-proliferative diabetic retinopathy, * Advanced peripheral neuropathy, active foot ulcer, Charcot foot, or significant sensory loss that may compromise safe test performance, * Presence of peripheral arterial disease, * Advanced renal failure, requirement for dialysis, or nephropathy that may compromise exercise safety, * Myocardial infarction within the previous 6 months, * Unstable ischemic heart disease or uncontrolled angina, * Resting blood pressure greater than 160/100 mmHg, * Presence of severe musculoskeletal, neurological, or vestibular disorders that may interfere with safe test performance, * High risk of balance loss or spatial disorientation in the mixed reality environment due to visual, auditory, or balance impairments, * Cognitive, behavioral, or compliance-related problems that may prevent completion of the study procedures.